Pseudomonas aeruginosa bacteremia remains one of the most serious hospital-acquired infections, with a mortality ranging from 20% to 38%.1–3 In recent years, several surveillance studies from Europe and the USA have reported increasing antimicrobial resistance rates in P. aeruginosa isolates, usually involving intensive care units (ICUs), but also affecting general wards and outpatient populations